Research Highlights Important Indicators Of Early-Stage Ovarian Cancer

Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Women's Health / Gynecology;  Cancer / Oncology
Article Date: 09 Nov 2007 - 13:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment. The findings show that the difference between life and death can many times be explained by the different biological properties of the tumors. Understanding ovarian cancer biomarkers, such as clear cell tumors, and the exploration of specific tumor-targeted therapy, such as DNA profiling, will improve early stage diagnosis.

"Our findings show that continued research into identifying early-stage indicators for ovarian cancer will have a dramatic impact on long-term patient survival. Current practices, such as lymph node sampling, present only the first step towards an eventual cure," says Ingiridur Skírnisdottir, lead author of the study.

Currently, less than 30 percent of women with ovarian cancer are diagnosed in the early stages of the disease, when it is confined to the ovaries (stage I) or when the spread has been limited to the pelvis (stage II). Although the long-term prognosis is better for patients with early-stage disease (10-year survival rates range from 50-70 percent) than for patients with advanced disease (where the 10-year survival rate is only 15-25 percent), up to 50 percent of women with early-stage ovarian cancer will eventually relapse and succumb to ovarian cancer.

International Journal of Gynecological Cancer presents papers from throughout the global community of researchers covering many topics including basic science, epidemiology, diagnostic techniques, surgery, radiotherapy, chemotherapy, pathology and experimental studies. The Journal allows you to call on a roster of international experts for the latest research, advice, and knowledge in order to provide the best treatment for your patients. For more information, please visit http://www.blackwellpublishing.com/ijg.

Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit http://www.blackwellpublishing.com or http://interscience.wiley.com.